返回排名列表

Fortive Corp (FTV)

合理估值
TechnologyScientific & Technical InstrumentsUnited States

基本面

55

价格

$55.13

市值

$17.00B

第一部分 · 这家公司值多少

概览

Fortive is a US industrial technology company that designs, makes and sells professional instruments, connected hardware, consumables and workflow software used to keep physical operations running safely and efficiently. After spinning off its Precision Technologies business as Ralliant Corporation on 28 June 2025, Fortive reports through two segments: Intelligent Operating Solutions, which sells test and measurement instruments, gas-detection equipment and facility, asset and EHS management software under brands such as Fluke, Industrial Scientific, Accruent, Gordian, ServiceChannel and Intelex; and Advanced Healthcare Solutions, which sells sterilization systems and consumables, instrument tracking, biomedical test tools, radiation dosimetry and clinical documentation software under brands such as Advanced Sterilization Products (ASP), Censis, Fluke Biomedical, Landauer and Provation. Its customers are electrical engineers, maintenance technicians, facility and safety managers, and hospitals and surgery centres. Fiscal 2025 revenue was $4,159.1 million.

盈利方式

Revenue comes partly from one-off sales of instruments and capital equipment through distributors and a direct sales force, and partly from a recurring stream: consumables and service contracts tied to an installed base (notably sterilization consumables and dosimetry badge services), plus software sold on subscription or licence with maintenance. At the 2025 separation Fortive described the remaining company as having roughly 50% recurring revenue; the 10-K itself does not restate that figure. The 10-K notes that capital equipment and sterilization consumable sales are often stronger in the fourth calendar quarter, but that the company as a whole is not subject to material seasonality.

分部营收

Intelligent Operating Solutions68.7%

Advanced instrumentation, connected devices, software and services for mission-critical maintenance, measurement, condition monitoring, worker safety and facility and asset management. Sold to electrical engineers, technicians, facility managers and first responders in manufacturing, process industries, utilities and healthcare. Sales were $2,856.3 million in fiscal 2025.

Advanced Healthcare Solutions31.3%

Workflow solutions for healthcare providers: instrument sterilization systems and consumables, surgical instrument tracking, biomedical test tools, radiation detection and dosimetry services, and clinical documentation and productivity software. Sold to hospitals, surgery centres and medical device makers. Sales were $1,302.8 million in fiscal 2025.

护城河

品牌 · 狭窄

Fortive's own filing says management believes the company holds a market leadership position in most of the markets it serves, and it markets through long-established professional brands — Fluke, Industrial Scientific, ASP, Landauer — where brand name recognition is listed among the key competitive factors, alongside price, quality, applications expertise, distribution channel access and service. Part of the revenue is attached to an installed base of equipment that consumes proprietary consumables and service, which tends to make the relationship sticky. The filing does not quantify switching costs, market shares or barriers to entry, and it describes competition as intense in every business, so the advantage should be read as real but not fortress-like.

需求驱动因素

中度周期性

Demand splits in two. The larger Intelligent Operating Solutions segment sells tools and instruments used in maintenance and repair, which follows industrial activity and maintenance budgets more than new plant construction, and software for facilities and assets that renews; it is exposed to the industrial cycle but cushioned by replacement and consumable demand. Advanced Healthcare Solutions follows hospital procedure volumes and capital budgets, which are steadier through a downturn, though equipment purchases can be deferred. Fortive's own risk factors name the growth rate and cyclicality of its markets as a risk; the 10-K says capital equipment and sterilization consumable sales are often stronger in the fourth calendar quarter but that the company as a whole is not subject to material seasonality.

主要风险

  • Global economy and end-market conditions — Fortive lists conditions in the global economy, in the markets it serves and in financial markets as able to adversely affect its business and results, and separately flags the growth rate and cyclicality of those markets as a risk.
  • Supply chain, manufacturing capacity and input costs — The company cites challenges in managing manufacturing capacity and its supply chain, and fluctuations in the cost of commodities and components, as risks to its cost structure and ability to deliver.
  • Competition and dependence on new products — Fortive discloses that it faces intense competition and that its results depend on successfully developing and launching new products and software; failure to innovate at the pace of its markets is listed as a risk.
  • Cybersecurity and product defects — Risk factors cover cybersecurity incidents and data breaches — relevant for a business selling connected devices and clinical software — as well as product defects and the resulting liability and recall exposure.
  • Healthcare and environmental regulation — Compliance with healthcare regulation, with changing industry standards and with environmental, health and safety requirements is disclosed as a risk, as are liabilities arising from those requirements.
  • Acquisitions, divestitures and separation-related liabilities — Fortive flags execution risk in its capital allocation, acquisitions and integrations, contingent liabilities retained from divestitures, indemnification obligations linked to Ralliant and Vontier, and the tax risks arising from the separation transactions.
  • International operations, trade and currency — The filing lists the risks of operating internationally, volatility in trade relations, and adverse movements in foreign currency exchange rates.
  • Goodwill impairment and debt — Because Fortive has grown by acquisition, it discloses the risk of impairment of goodwill and other intangible assets, along with risks tied to its debt obligations and access to financing.

客户集中度

The 10-K does not disclose a customer concentration figure: there is no statement that any single customer accounted for 10% or more of sales, and no top-customers share is given. Fortive describes selling through a combination of direct sales forces and distributors and channel partners to a broad base of industrial, utility, government and healthcare customers, and lists the loss of distributor and channel partner relationships — not the loss of a single end customer — among its risk factors.

看多理由

Buyers argue that after the Ralliant spin-off Fortive is a simpler, higher-margin company: two segments built on recognised professional brands, with roughly half the revenue recurring through consumables, dosimetry services, maintenance and software subscriptions, which should make results less volatile than a pure instrument maker's. They point to management's stated market leadership in most served niches, to a healthcare segment tied to procedure volumes rather than industrial capex, and to a balance sheet freed of the spun-off business that can fund buybacks and bolt-on acquisitions of the kind Fortive has assembled its portfolio with.

看空理由

Sellers fear that growth is thin: consolidated revenue rose 1.9% in fiscal 2025, with Advanced Healthcare Solutions up only 1.2%, so the company is compounding slowly for a business classified as technology. They worry that a portfolio assembled through acquisitions carries a large goodwill and intangible balance that the company itself flags as impairment-exposed, and debt to service; that competition is described as intense in every line, with results depending on a continuous stream of new products; and that the industrial half of the business follows maintenance budgets and the market cycles Fortive lists among its own risk factors. Separation leaves indemnification obligations toward Ralliant and Vontier and tax exposure if the spin-offs are challenged.

Generated on 2026年9月18日 with claude-haiku-4-5 — shared with all users

Direct competitors

Who this company fights with for the same customers

Compare

Generated on 2026年9月18日 with claude-haiku-4-5 — shared with all users

P/E: 36.2Score: 71Market cap: $57.70B

AMETEK sells electronic instruments and process, test and calibration equipment to the same plant engineers, technicians and maintenance teams that buy Fortive's Fluke instrumentation.

P/E: 49.9Score: 71Market cap: $61.24B

Keysight is the main rival in electronic test and measurement instruments, overlapping with Fluke on the electrical and electronic testing tools used by engineers and field technicians.

P/E: 9.7Score: 61Market cap: $67.12B

Honeywell sells gas detection and connected-worker safety gear plus building and asset management software, overlapping with both Industrial Scientific and Fortive's Accruent and ServiceChannel facility software.

STERIS plcSTE

STERIS competes head-on with Fortive's Advanced Sterilization Products and Censis businesses for hospital sterile-processing departments, selling sterilizers, endoscope reprocessing and instrument-tracking systems.

MSA Safety IncorporatedMSA

MSA Safety competes with Fortive's Industrial Scientific for the same industrial-safety budgets, selling portable and fixed gas detection and connected-worker monitoring to oil & gas, mining and manufacturing sites.

Getinge ABNot tracked

The Swedish group is, with STERIS, the other global supplier of hospital sterilization and endoscope reprocessing equipment, competing directly with Fortive's ASP sterilizers.

资产负债表与流动性

营收

$4.24B

最近12个月(截至2026/4/3)

净利润

$544M

最近12个月(截至2026/4/3)

自由现金流

$978M

股东权益合计

$6.45B

负债合计

$5.28B

流动比率

0.71

利息覆盖率

5.98

债务/EBITDA

3.09

每股收益

营收与净利润

自由现金流

收入构成

历史财务表

利润率变化

债务变化

债务负担有多重

增长一览表

增长 — 营业收入

公允价值估算

一般情形合理估值

公允价值

$47.62

当前价格

$55.13

安全边际

-15.8%

公允价值区间

$30.95 - $64.29

所用估值方法之间的离散区间,并非经过统计校准的置信区间。

估算方法

分析师目标价:$64.31
现金流折现法(DCF):$60.28
市盈率法(P/E):$33.21
格雷厄姆成长公式:$14.14
盈利能力价值(EPV):$19.58
合理市净率(P/B):$14.73
股息折现模型(戈登模型):$4.64
P/FFO(运营资金):$53.36
周期中段收益:$58.32
市销率法(P/S):$71.61
分析师共识:持有 (7B / 12H / 2S)
最近财报超预期:+3.44%

估值指标

市盈率(P/E)

32.82

ROE

9.0%

市净率(P/B)

2.75

P/FCF

17.52

毛利率

63.3%

ROIC

6.3%

盈利能力雷达图

价值创造(经济护城河)

ROIC

6.3%

WACC

9.0%

ROIC − WACC

-2.7 pp

ROIC 低于资本成本:公司每投入一美元都在毁灭价值。

基本面分析标准

通过(16)

  • ROIC 6.3%
  • Gross Margin 63.3%
  • P/FCF 17.52
  • P/B Ratio 2.75
  • Debt/Equity ratio
  • Operating Margin 17.6%
  • Positive Free Cash Flow
  • CapEx intensity
  • Interest Coverage
  • Debt/EBITDA
  • Return on Tangible Assets
  • ROE 8.5%
  • Earnings Surprise avg 9.0%
  • Earnings Quality (OCF/NI) 1.98
  • Share Dilution -5.1%
  • Piotroski F-Score 6/9

未通过(10)

  • EPS shows upward trend
  • EPS CAGR -3.50%
  • Price CAGR 4.92%
  • Current Ratio
  • Low reliance on intangibles
  • Price below Graham Number
  • DCF valuation (Fairly valued)
  • Revenue Growth 5Y -2.1%
  • Analyst Consensus 33% Buy
  • Net Margin Trend 12.8% vs 19.5%

不可用(2)

  • Dividend Payout NaN%
  • PEG Ratio (need PE > 0 and growth > 0)

Piotroski F-评分

6/9

信号混杂:部分领域需关注

score
criteria

盈利质量

1.98

高质量:盈利有现金流支撑

股权稀释

-5.1%

正在回购股份,对股东友好

机构持股

公司治理

管理团队

姓名职位年龄
Mr. Olumide O. Soroye J.D.President, CEO & Director52
Mr. Mark D. Okerstrom J.D.Senior VP & CFO52
Mr. Peter C. Underwood J.D.Senior VP & Chief Legal Officer55
Mr. Christopher M. MulhallChief Accounting Officer51
Mr. Victor P. Fetter IIISenior VP & Chief Technology and Business System Officer56
Ms. Christina JonesVice President of Investor Relations-
Ms. Amee DesjourdySenior VP & Chief People Officer52
Mr. Parker BurkePresident of Fluke & Group President of Connected Reliability Group (CRG)-
Mr. Arul ElumalaiPresident of Gordian and Group President of Facilities & Asset Lifecycle (FAL) Group-
Mr. Chad RohrerPresident of ASP & Group President of Infection Prevention Group (IPG)-

审计风险

2

董事会风险

1

薪酬风险

9

股东权利风险

7

第二部分 · 价格与买入时机

这一部分不判断公司是否值得拥有:它帮助你在基本面说服你之后,选择何时买入。包含:技术分析、潜力、历史回撤、Gamma 敞口。

文件

  • 年度报告(10-K)

    对公司业务、财务业绩和风险的年度概述。

    提交日期:2026-02-25

    查看文件
  • 季度报告(10-Q)

    最近三个月财务表现的最新情况。

    提交日期:2026-07-29

    查看文件
  • 临时报告(8-K)

    关于重大事件(如管理层变动或重要公告)的通知。

    提交日期:2026-09-10

    查看文件

via SEC EDGAR

损益历史

via SEC EDGAR

Latest News

Recent headlines for FTV, sourced from Markets Gazette.

No recent news for FTV.